Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Hematologic Profiles in the Phase 3 APEX Trial.

Sagar Lonial, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3474.

https://doi.org/10.1182/blood.V106.11.3474.3474

Published: 2005

Journal Articles

NF-κB Blockade Induces Apoptosis and Decreases Costimulatory Molecules and IL-12 Secretion of Dendritic Cells, Altering DC Maturation: Role in Induction of Tolerance after Transplantation.

Luis I. Sanchez Abarca, PhD, Jose A. Perez-Simon, MD, PhD, Belen Blanco, PhD, Norma Gutierrez, MD, PhD, Juan Mateos, Belen Vidriales, MD, PhD, Natalia Lopez-Holgado, PhD, Mercedes Alberca, Eva Villaron, D. Schenkein, PhD, Consuelo Canizo, MD, PhD, Jesus F. San Miguel, MD, PhD

Blood (2005) 106 (11): 2465.

https://doi.org/10.1182/blood.V106.11.2465.2465

Published: 2005

Journal Articles

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

G. Mulligan, C. Mitsiades, B. Bryant, F. Zhan, W. Cheng, S. Eschrich, B. Burrington, P. Richardson, W. Trepicchio, J. Shaughnessy, L. Bergsagel, A. Damokosh, A. Boral, D. Esseltine, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 3491.

https://doi.org/10.1182/blood.V106.11.3491.3491

Published: 2005

Journal Articles

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

J.F. San Miguel, P. Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2005) 106 (11): 366.

https://doi.org/10.1182/blood.V106.11.366.366

Published: 2005

Journal Articles

Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.

Sundar Jagannath, B. Durie, J. Wolf, E. Camacho, D. Irwin, J. Lutzky, M. McKinley, E. Gabayan, A. Mazumder, J. Crowley, R. Vescio, D. Schenkein

Blood (2005) 106 (11): 783.

https://doi.org/10.1182/blood.V106.11.783.783

Published: 2005

Journal Articles

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.

Blood (2005) 106 (11): 786.

https://doi.org/10.1182/blood.V106.11.786.786

Published: 2005

Journal Articles

Bortezomib Induces Selective Depletion of Activated T Lymphocytes and Modifies the Cytokine’s Production Pattern.

Belen Blanco, PhD, Jose A. Perez-Simon, MD, PhD, Luis I. Sanchez-Abarca, PhD, Xonia Carvajal-Vergara, Juan Mateos, Belen Vidriales, MD, PhD, Natalia Lopez-Holgado, PhD, Mercedes Alberca, Eva Villaron, D. Schenkein, PhD, Consuelo Canizo, MD, PhD, Atanasio Pandiella, MD, PhD, Jesus F. San Miguel, MD, PhD

Blood (2005) 106 (11): 615.

https://doi.org/10.1182/blood.V106.11.615.615

Published: 2005

Journal Articles

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

Paul Richardson, P. Sonneveld, M. Schuster, D. Irwin, E. Stadtmauer, T. Facon, J. Harousseau, D. Ben-Yehuda, S. Lonial, H. Goldschmidt, D. Reece, J. San Miguel, J. Blade, M. Boccadoro, J. Cavenagh, W. Dalton, A. Boral, D. Schenkein, K. Anderson

Blood (2004) 104 (11): 1479.

https://doi.org/10.1182/blood.V104.11.1479.1479

Published: 2004

Journal Articles

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.

Blood (2004) 104 (11): 3462.

https://doi.org/10.1182/blood.V104.11.3462.3462

Published: 2004

Journal Articles

Bortezomib in Combination with Melphalan in the Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study.

James Berenson, MD, H. Yang, R. Swift, K. Sadler, R. Vescio, J. Adams, D. Schenkein

Blood (2004) 104 (11): 209.

https://doi.org/10.1182/blood.V104.11.209.209

Published: 2004

NARROW

Hematologic Profiles in the Phase 3 APEX Trial.

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

NF-κB Blockade Induces Apoptosis and Decreases Costimulatory Molecules and IL-12 Secretion of Dendritic Cells, Altering DC Maturation: Role in Induction of Tolerance after Transplantation.

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.

Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.

Bortezomib Induces Selective Depletion of Activated T Lymphocytes and Modifies the Cytokine’s Production Pattern.

Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.

Bortezomib in Combination with Melphalan in the Treatment of Relapsed or Refractory Multiple Myeloma: A Phase I/II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only